Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNISoN: Nivolumab and Ipilimumab in nccRCC
NCT03177239Phase 2Unknown
- Sponsor
- ANZUP Cancer Trials Group
- Start
- Oct 2017
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in non-clear cell renal cell carcinoma (nccRCC), sponsored by ANZUP Cancer Trials Group. Status: unknown.
02
Drugs
nivolumabipilimumab
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT03177239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03177239.